Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
BioLife Solutions, Inc.
BLFS
NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $1.4B
$28.11
▼ -1.33%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$17.86 - $30.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 25.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary biopreservation formulations with patent protection and regulatory validation
- Integrated ecosystem of complementary products creating customer lock-in and switching costs
- Established relationships with leading cell and gene therapy manufacturers and research institutions
- Cloud-connected smart logistics technology providing real-time monitoring and data analytics
- Decades of industry expertise and scientific credibility since 1987 founding
Bear Case
2 risks
- Above-average volatility (beta 2.0).
- Growth premium of 16.5x vs Medical Devices peers. Significant premium - requires sustained high growth to justify.
Growth
Turning profitable
Steady revenue growth (17% YoY)
Value
Growth premium of 16.5x vs Medical Devices peers. Significant premium - requires sustained high growth to justify.
Momentum
Hot
+46.0% over 3m
Quality
Excellent
High-growth business (8% revenue growth, 64% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying BLFS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 7, 2026
Reported EPS of $0.04 vs $0.01 consensus (+300.0% surprise). Revenue of $27.5M vs $25.7M expected (+7.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+300.0%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
-120%
+30%
+29%
-8%
—
+15%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$19.7M
$30.6M
-$3.4M
$23.9M
$25.4M
$28.1M
$18.8M
$27.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
4.3%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
No analyst coverage on file for this stock yet.